Exposure‐response analysis for evaluation of semaglutide dose levels in type 2 diabetes

AIMS: To evaluate dose levels for semaglutide, a glucagon‐like peptide‐1 analogue approved for the treatment of type 2 diabetes, by examining the effects of demographic factors on efficacy and safety in an exposure‐response analysis. METHODS: We analysed data from 1552 adults from four randomized ph...

Descripción completa

Detalles Bibliográficos
Autores principales: Petri, Kristin C. C., Ingwersen, Steen H., Flint, Anne, Zacho, Jeppe, Overgaard, Rune V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099226/
https://www.ncbi.nlm.nih.gov/pubmed/29748996
http://dx.doi.org/10.1111/dom.13358

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099226/
https://www.ncbi.nlm.nih.gov/pubmed/29748996
http://dx.doi.org/10.1111/dom.13358

Ejemplares similares